Alnylam Pharmaceuticals Inc. (ALNY) said it has achieved full patient accrual in its Envision Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 or ALAS1 for the treatment of acute hepatic porphyrias, or AHPs.
from RTT - Biotech https://ift.tt/2LbRR7n
via IFTTT
No comments:
Post a Comment